Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma

Baertsch, Marc-Andrea; Mai, Elias K.; Hielscher, Thomas; Bertsch, Uta; Salwender, Hans J.; Munder, Markus; Fuhrmann, Stephan; Dührsen, Ulrich; Brossart, Peter; Neben, Kai; Schlenzka, Jana; Kunz, Christina; Raab, Marc S.; Hillengaß, Jens; Jauch, Anna; Seckinger, Anja; Hose, Dirk; Luntz, Steffen; Sonneveld, Pieter; Lokhorst, Henk; Martin, Hans; Goerner, Martin; Hoffmann, Martin; Lindemann, Hans-Walter; Bernhard, Helga; Blau, Igor W.; Scheid, Christof; Besemer, Britta; Weisel, Katja C.; Hänel, Mathias; Dürig, Jan; Goldschmidt, Hartmut

Lenalidomide (LEN) maintenance (MT) post autologous stem cell transplantation (ASCT) is standard of care in newly diagnosed multiple myeloma (MM) but has not been compared to other agents in clinical trials. We retrospectively compared bortezomib (BTZ; n = 138) or LEN (n = 183) MT from two subsequent GMMG phase III trials. All patients received three cycles of BTZ-based triplet induction and post-ASCT MT. BTZ MT (1.3 mg/m² i.v.) was administered every 2 weeks for 2 years. LEN MT included two consolidation cycles (25 mg p.o., days 1–21 of 28 day cycles) followed by 10–15 mg/day for 2 years. The BTZ cohort more frequently received tandem ASCT (91% vs. 33%) due to different tandem ASCT strategies. In the LEN and BTZ cohort, 43% and 46% of patients completed 2 years of MT as intended (p = 0.57). Progression-free survival (PFS; HR = 0.83, p = 0.18) and overall survival (OS; HR = 0.70, p = 0.15) did not differ significantly with LEN vs. BTZ MT. Patients with

Preview

Cite

Citation style:

Baertsch, Marc-Andrea / Mai, Elias / Hielscher, Thomas / et al: Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma. 2021.

Rights

Use and reproduction:

Export